CorMedix (CRMD) Long-Term Investments (2024 - 2026)
CorMedix (CRMD) posted Long-Term Investments of $23.8 million for Q4 2025, up 3.94% sequentially from $22.9 million in Q3 2025, and up 22581.9% YoY from N/an in Q4 2024.
CorMedix (CRMD) Long-Term Investments (2024 - 2026) Analysis & Trends
CorMedix has reported Long-Term Investments for 2 years, with the latest figure at $23.8 million in Q4 2025.
- Quarterly Long-Term Investments rose 22581.9% year-over-year to $23.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $23.8 million (up 22581.9% YoY) and the FY2025 annual result came in at $23.8 million, up 22581.9% from the prior year.
- Long-Term Investments rose to $23.8 million in Q4 2025 per CRMD's latest filing, from $22.9 million in the prior quarter.
- Over five years, Long-Term Investments peaked at $23.8 million in Q4 2025 and troughed at $105000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Long-Term Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.79 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 9.83 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 1.77 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 22.17 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 372.10 Mn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | 27.17 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 27.17 Mn |
| Dec 31, 2025 | 23.82 Mn |
| Sep 30, 2025 | 22.91 Mn |
| Dec 31, 2024 | 105,000.00 |